about
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsNew approaches for precise response evaluation in hepatocellular carcinomaBeyond the GIST: mesenchymal tumors of the stomachManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Validation of novel imaging methodologies for use as cancer clinical trial end-pointsA phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysisPhase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markersAbsence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Response Evaluation of Chemotherapy for Lung Cancer.UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylateChoi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP studyTargeted therapy for cancer: the gastrointestinal stromal tumor model.RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.Melanoma: a model for testing new agents in combination therapies.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinCancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Targeted therapies in renal cell cancer: recent developments in imagingRexin-G, a targeted genetic medicine for cancer.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Updates on the management of gastrointestinal stromal tumors.Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumorClinical and therapeutic considerations of GISTTumor volume as an alternative response measurement for imatinib treated GIST patients.Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinibTreatment of gastrointestinal stromal tumor: focus on imatinib mesylate.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.Characteristics of computed tomography imaging of gastrointestinal stromal tumor (GIST) and related diagnostic problems.Clinical utility of quantitative imaging.
P2860
Q26863326-656D352E-97DD-4E64-819D-A3ED8595AB3AQ26866367-636487D3-31DB-4290-947C-CEDFB984BCA4Q27028116-C93D2BEA-2C93-4F74-BFC1-F42106753348Q28087771-4F49E93F-8C96-41BB-951B-48B3AA7AE079Q28391684-304FB473-D5D1-41A6-9094-5C3156E9B5DDQ28765146-F838284F-F0B2-4770-9861-4B691C532589Q30437854-402FDBCD-3793-4A39-BE78-ACE4F83F557FQ33394106-21001663-81B0-4F43-A636-12C43837C135Q33397006-7BE925EB-48A5-4966-BAD3-AF076E74596EQ33407600-235FBFB2-F644-42E4-9C96-7E6D16470D5AQ33410655-F90DAA14-7C3F-4A96-8B39-9AE5E0AF39EAQ33414685-41696619-6F87-4ACB-880E-E8618E39D1A9Q33417933-8B3EFBDB-2E8B-451C-829A-5F3087FA02BEQ33561602-7F350020-E1BB-43B5-800F-E7578F712E98Q33567345-46507810-5B8F-4B08-B463-9F5C99B081DEQ33612778-3263900E-C06A-49C8-9B42-07B5DC1F1758Q33644791-76F0E935-C25A-4897-9310-E9C5257937F7Q33666010-DF63C2F6-1860-42FA-9A96-B614113F7532Q33708158-F9A0258D-38D1-4756-8400-FEBDB3FD26FEQ33755947-E5D2FE3F-451C-47BE-8295-1051254AFDF2Q33807742-38FFDB9E-F137-42DA-ABB6-3FBEC565EB2FQ33857343-1421200E-D5EE-4FEF-9592-924927351E28Q33863916-D56B9BF9-1480-4637-9F7F-F7B8670CCC21Q33921067-036A8C22-4FF9-4F37-B59B-F983862824AFQ34018372-9A58B79C-5B6F-4B7C-821E-C203FEA76026Q34023973-4F5135A2-171A-400C-87A0-32468AE35DFCQ34088696-E6F01D6E-334C-4FE4-9F8A-8BB051E880CFQ34109646-CB20B59F-DC09-4752-A96D-5ADEB31F54D6Q34202396-E04B2704-AF9E-46C7-9115-34608D926243Q34256921-A1ADF5D4-3653-44B4-BA53-BA37B22B46B4Q34305765-97D642DC-E6C9-4073-977E-8D789D7D8B88Q34341168-E1F90687-C958-497F-B0A0-3C8B71DCEC6DQ34469701-DFC101C8-2759-4433-88A8-86D888DF2F89Q34499075-0EBEEA25-D62B-4113-A0FB-810046549965Q34537285-8BD8731F-8D14-46C2-8B1D-94CD6D8AE2D1Q34566471-519E3407-1937-423E-AF9F-EE3DA3511741Q34596126-01A767AB-7F2F-4151-BEFE-8FEC72728EA3Q34636081-A269B5D6-AB63-464A-97E1-FE4AB8EF6C48Q34640458-28669B78-BB28-4DC0-ACE7-6B7F9084F51BQ34656915-6612F90B-3DB3-4DE3-A841-D9E63424BC8F
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
We should desist using RECIST, at least in GIST.
@en
type
label
We should desist using RECIST, at least in GIST.
@en
prefLabel
We should desist using RECIST, at least in GIST.
@en
P2093
P356
P1476
We should desist using RECIST, at least in GIST.
@en
P2093
Chuslip Charnsangavej
Donald A Podoloff
Haesun Choi
Homer A Macapinlac
Lei L Chen
Michael A Burgess
Robert S Benjamin
Shreyaskumar R Patel
P304
P356
10.1200/JCO.2006.07.3411
P407
P577
2007-05-01T00:00:00Z